丹红注射液联合瑞舒伐他汀治疗不稳定型心绞痛患者的疗效及对血清TNF-α、hs-CRP和IL-6观察组

Efficacy of Rosuvastatin Combined with Danhong Injection in the Treatment of Unstable Angina Pectoris and Influence on Serum Levels of TNF-α,hs-CRP and IL-6

目的:探讨丹红注射液联合瑞舒伐他汀治疗不稳定型心绞痛(UAP)的临床疗效及其对患者血清肿瘤坏死因子α(TNF-$)、高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平的影响。方法:72例UAP患者随机分为对照组和观察组各36例。两组患者均给予常规治疗,对照组患者在常规治疗基础上给予口服瑞舒伐他汀片10 mg,po,qd治疗,观察组患者则在对照组的基础上再加用丹红注射液30 ml,ivd,qd。两组患者均连续治疗2周。观察两组患者的临床疗效及药品不良反应发生情况,记录两组治疗前后心绞痛发作频度及持续时间。比较治疗前后两组患者血脂及血清TNF-$、hs-CRP和IL-6水平变化。结果:观察组治疗总有效率为91.67%,显著高于对照组的72.22%(P<0.05);观察组患者的心绞痛发作频度和持续时间均显著低于对照组(P<0.05)。治疗后,两组患者的TG、TC、LDL-C等血脂指标水平以及血清TNF-$、hs-CRP和IL-6水平均较治疗前显著下降,HDL-C水平则较治疗前显著升高,差异均有统计学意义(P<0.05);且观察组TG、TC、LDL-C水平及血清TNF-$、hs-CRP和IL-6水平均显著低于对照组,HDL-C水平显著高于对照组(P<0.05)。结论:丹红注射液联合瑞舒伐他汀治疗不稳定型心绞痛,可有效改善患者的临床症状,减少心绞痛发作频度及持续时间,同时可降低血清TNF-$、hs-CRP和IL-6水平,抑制炎症反应,安全有效,值得应用于临床。

Objective： To discuss the efficacy of rosuvastatin combined with Danhong injection in the treatment of unstable angina pectoris （UAP） and the influence on serum levels of TNF-α, hs-CRP and IL-6. Methods： Totally 72 patients with UAP were random- ly divided into the control group （n = 36） and the observation group （n = 36）. All the patients received the conventional therapy. The control group was given rosuvastatin tablets,10 mg,po, qd on the basis of the conventional therapy, while the research group was trea- ted with Danhong injection 30ml, ivd, qd on the basic of the control group. All the patients were treated for 2 weeks. The improvements of clinical symptoms and electrocardiogram, and the adverse reactions before and after the treatments were observed. The frequency of onset and duration before and after the treatment were recorded. The levels of blood lipid, TNF-α, hs-CRP and IL-6 before and after the treatment were detected. Results： The total effective rate of the observation group was 91.67%, which was significantly higher than that （72.22%） of the control group （ P 〈 0.05 ）. The seizure frequency and duration of the research group were significantly low- er than those of the control group （ P 〈 0.05 ）. After the treatment, the lipid indices such as TG, TC and LDL-C, and serum levels of TNF-α, hs-CRP and IL-6 of the two groups decreased significantly, while HDL-C significantly increased, and the differences were sta- tistically significant （ P 〈 0.05 ）. The levels of TG, TC, LDL-C, TNF-α, hs-CRP and IL-6 were significantly lower in the observation group than those in the control group, while HDL-C was significantly higher than that in the control group （ P 〈 0.05 ）. Conclusion： Danbeng injection and rosuvastatin can effectively improve the clinical symptoms of UAP patients, reduce angina frequency and dura- tion, and decrease serum levels of TNF-α, hs-CRP and IL-6 to inhibit inflammation, which is safe and effective, and worthy of clinical application.